About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Drug Class Review
Current Evidence and Future Directions
The question of whether the pleiotropic effects of combining an ARB with an ACE inhibitor would provide a greater vascular advantage over either class of agent alone has not been directly addressed in clinical trials to date.
Mark A. Munger, PharmD
Drug Use Evaluation
Methylnaltrexone relieves opioid-induced constipation; too often, however, it is prescribed inappropriately. Implementing order sets may help to reduce misuse.
Jack L. Watkins, PharmD; Karen R. Eckmann, PharmD; Morgan L. Mace, PharmD; Jane Rogers, PharmD; Ginger Langley, PharmD, BCPS, BCNSP; and Wendy Smith, PharmD, BCPS
Pharmacy Systems Will Be Updated Slowly but Surely
Millions of dollars are at stake as hospitals rush to adopt EHRs. However, few hospitals have certified systems in place to meet the definition of meaningful use.
Topics include therapies for breast cancer, prevention of skeletal-related events in cancer patients, and pseudobulbar affect.
Marvin M. Goldenberg, PhD, RPh, MS
American Heart Association 2010 Scientific Sessions and American Society of Nephrology: Renal Week 2010
The cardiology meeting covered rivaroxaban, clopidogrel, and statins. Nephrology topics included ezetimibe/simvastatin, eculizumab, and bardoxolone.
Dr. David Nash looks back on a year of important advances by Thomas Jefferson University Hospital’s medication quality subcommittee.
David B. Nash, MD, MBA
Standardizing dosing measurements and units is essential for avoiding mistakes in administering intravenous agents.
Matthew Grissinger, RPh, FASCP
But They Are Not Yet Recovering Overhead Costs for Expensive Drugs
Hospital pharmacies will be receiving higher Medicare payments in 2011, but they are still not being compensated sufficiently for their overhead costs for expensive drugs.
FDA approvals, drug indications, and updates